Iossa Vincenzo, Pandolfo Savio Domenico, Buonopane Roberto, Di Girolamo Antonio, Fiore Felice, Sessa Gaetano, Vitale Raffaele, Ferraro Angelo, Amodeo Enrico Maria, Porcaro Piercarmine, Punzi Ernesto, Lombardi Giulio, Imperatore Vittorio
Department of Urology, Azienda Ospedaliera "S.G. Moscati", Avellino, Italy.
Department of Urology, University of L'Aquila, 67100, L'Aquila, Italy.
Int Urol Nephrol. 2025 Apr;57(4):1097-1104. doi: 10.1007/s11255-024-04238-8. Epub 2024 Nov 22.
The aim of this study is to compare perioperative, functional, and oncological outcomes between robot-assisted partial nephrectomy (RAPN) and cryoablation (CRYO), based on a 3-year experience at our Institution. Additionally, a secondary aim is to conduct a comparative cost analysis between the two procedures.
A retrospective analysis was conducted, including patients who underwent RAPN or CRYO between January 2020 and December 2023. Group 1 consisted of 59 patients who underwent RAPN, while Group 2 included 38 patients who had CRYO. The evaluation parameters included baseline characteristics, perioperative, functional, and oncological outcomes, as well as total hospitalization costs.
Operative time (OT), average length of hospital stay (LOS), and emetic blood loss (EBL) were significantly lower in the CRYO group. Furthermore, CRYO showed a significantly lower rate of postoperative complications of any grade (7.8% vs 16.9%); however, this was associated with a considerably higher recurrence rate (5.7% vs 1.7%). No substantial differences were found in long-term functional outcomes (ΔeGFR). In terms of costs, CRYO was more cost-effective than RAPN (€5473 vs €10,672), although the gap was partially offset by a higher reimbursement "DRG" rate for robotic partial nephrectomy (€7386 vs €4384).
Robot-assisted partial nephrectomy (RAPN) remains the preferred option for treating small renal masses (sRM), providing excellent oncological results and acceptable morbidity. However, percutaneous cryoablation is a valid alternative, particularly for patients unfit for surgery, as long as meticulous postoperative follow-up is carried out.
本研究旨在根据我们机构3年的经验,比较机器人辅助部分肾切除术(RAPN)和冷冻消融术(CRYO)在围手术期、功能和肿瘤学方面的结果。此外,次要目的是对这两种手术进行成本比较分析。
进行了一项回顾性分析,纳入了2020年1月至2023年12月期间接受RAPN或CRYO的患者。第1组由59例行RAPN的患者组成,第2组包括38例行CRYO的患者。评估参数包括基线特征、围手术期、功能和肿瘤学结果以及总住院费用。
CRYO组的手术时间(OT)、平均住院时间(LOS)和呕吐物失血(EBL)显著更低。此外,CRYO显示任何级别的术后并发症发生率显著更低(7.8%对16.9%);然而,这与相当高的复发率相关(5.7%对1.7%)。长期功能结果(ΔeGFR)未发现实质性差异。在成本方面,CRYO比RAPN更具成本效益(5473欧元对10672欧元),尽管机器人部分肾切除术较高的“疾病诊断相关分组”(DRG)报销率部分抵消了这一差距(7386欧元对4384欧元)。
机器人辅助部分肾切除术(RAPN)仍然是治疗小肾肿块(sRM)的首选方案,可提供出色的肿瘤学结果和可接受的发病率。然而,经皮冷冻消融是一种有效的替代方法,特别是对于不适合手术的患者,只要进行细致的术后随访。